Dr. Moses is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-322-4020
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1994 - 1997
University of North Carolina HospitalsInternship, Internal Medicine, 1993 - 1994
University of North Carolina at Chapel Hill School of MedicineClass of 1993
Certifications & Licensure
TN State Medical License 1997 - 2025
AZ State Medical License 1997 - 1998
MN State Medical License 1995 - 1997
NC State Medical License 1993 - 1994- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2003
Clinical Trials
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Start of enrollment: 2013 Nov 01
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Publications & Presentations
PubMed
- New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: A case series.Megan Schneider, John Kramer, Aimee Banks, Harold Moses
Multiple Sclerosis. 2024-09-01 - 29 citationsBlocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism.Makoto Sano, Ryota Takahashi, Hideaki Ijichi, Kazunaga Ishigaki, Tomoharu Yamada
Gut. 2021-09-01 - 15 citationsSoluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.Ryota Takahashi, Hideaki Ijichi, Makoto Sano, Koji Miyabayashi, Dai Mohri
Scientific Reports. 2020-12-03
Press Mentions
MS Diagnosis: What to Know About Tests and Treatments for Multiple SclerosisNovember 12th, 2021
Functional Cooperation Between Co-Amplified Genes Promotes Aggressive Phenotypes of HER2-Positive Breast CancerMarch 9th, 2021
Special Symposium to Honor Moses’ Cancer Research ContributionsSeptember 21st, 2017- Join now to see all
Grant Support
- Tgf-Beta In Mammary Development And TumorigenesisNational Cancer Institute2003–2012
- TrainingNational Cancer Institute2011
- Planning And Evaluation CoreNational Cancer Institute2011
- Mmc, Vicc &Tsu: Partners In Eliminating Cancer Disparities ( 2 Of 3)National Cancer Institute2011
- Administration CoreNational Cancer Institute2011
- Role Of Fibroblasts, Myeloid Cells And Matrix In PDACNational Cancer Institute2010–2011
- Tgf-Beta Suppression And Promotion Of Mammary CarcinomasNational Cancer Institute2006–2011
- Planning And Evaluation CoreNational Cancer Institute2006–2010
- Paracrine Tgf-Beta Signaling In Breast Cancer Initiation And ProgressionNational Cancer Institute2006–2010
- MMC And Vicc: Partners In Eliminating Cancer DisparitiesNational Cancer Institute2006–2010
- Developmental FundsNational Cancer Institute2006–2010
- Assessing Antibiotic Therapy For Cpneumoniae In The CNS Of MS PatientsNational Center For Research Resources2005–2008
- Transgenic Mouse/Es Cell Shared ResourceNational Cancer Institute2004–2008
- Tgf-Beta In Mammary Development And TumorigenesisNational Cancer Institute2004–2008
- Comprehensive Mmc/Vicc Cancer Research PartnershipNational Cancer Institute2001–2006
- Overcoming Colorectal Cancer DisparitiesNational Cancer Institute2005
- TGF Beta Suppression And Promotion Of Mammary CarcinomasNational Cancer Institute2000–2005
- Assessing Antibiotic Therapy For C.Pneumoniae In The CNS Of MS PatientsNational Center For Research Resources2004
- Senior LeadershipNational Cancer Institute2004
- Protocol Specific Research SupportNational Cancer Institute2004
- Program Planning &EvaluationNational Cancer Institute2004
- DevelopmentNational Cancer Institute2004
- Data &Safety MonitoringNational Cancer Institute2004
- Mentored Patient-Oriented Research Career Development AwNational Center For Research Resources2000–2004
- National Cancer Institute Initial Review GroupNational Cancer Institute2000–2003
- Cancer Center Support GrantNational Cancer Institute1999–2003
- Core--Protocol Specific Research SupportNational Cancer Institute1999–2002
- Core--Developmental FundsNational Cancer Institute1999–2002
- Multidisciplinary Basic Research Training In CancerNational Cancer Institute1987–2001
- Transforming Growth Factors In Neoplastic TransformationNational Cancer Institute1986–1999
- Cancer CenterNational Cancer Institute1995–1998
- Mechanisms Of Transforming Growth Factor-Beta Resistance In Carcinoma CellsNational Cancer Institute1994–1997
- Growth Inhibitors Differentiation And CancerNational Cancer Institute1994–1997
- Joint Conference On Negative And Positive Growth ControlNational Cancer Institute1992
- Gordon Research Conf. On Peptide Growth FactorsNational Cancer Institute1988
- Mechanism Of Chemical Carcinogenesis In VitroNational Cancer Institute1985–1986
- Growth Factors And Receptors In Chemical TransformationNational Cancer Institute1985–1986
- Chemical Pathology Study SectionCenter For Scientific Review1985–1986
- Mechanism Of Chemical Carcinogenesis In VitroNational Cancer Institute1985
- Growth Factors And Receptors In Chemical TransformationNational Cancer Institute1985
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
